Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
The one-shot Johnson & Johnson vaccine could speed global uptake and help prevent the emergence of more SARS-CoV-2 variants in vulnerable low- and middle-income countries (LMICs). This latest vaccine approved by the US Food and Drug Administration and others in the pipeline may allay global shortages that have arisen due to wealthy countries’ grab for the lion’s share of initial vaccine supplies. The next wave of vaccine developers is ushering in new technologies to deal with fast-spreading variants and striking deals—not with the familiar COVID-19 vaccine makers, but with producers and institutes in LMICs. The flow of technology is not all one-way, either. Bharat Biotech of Hyderabad, India, which recently reported an efficacy rate of 81% in an interim read-out from a phase 3 trial of its whole-virion inactivated vaccine Covaxin, has lined up Ocugen to act as its US development and commercial partner.